Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04154501 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects
A Phase 1 study of Pain and Chronic Pain, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT04154501: Completed Phase 1 study of Pain and Chronic Pain, sponsored by Centrexion Therapeutics.
NCT04154501 is a Phase 1 study of Pain and Chronic Pain that has completed, run by Centrexion Therapeutics. The registered enrollment target is 68 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04154501, a Phase 1 study of Pain and Chronic Pain, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an open-label, 2-period crossover, food effect cohort.
Primary Outcome
Information regarding treatment emergent adverse events was collected during each dose cohort.
Conditions Studied
Interventions
- OTHER Other: Placebo
- DRUG CNTX-6016
Study Locations (1)
Kansas
- Altasciences Clinical Research - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-12-04 |
| Est. Completion | 2019-08-26 |
| Phase | Phase 1 |
What the finished NCT04154501 record still lists
NCT04154501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Other: Placebo is the first listed.
NCT04154501 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT04154501 about?
NCT04154501 is a clinical study titled "A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects". A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an open-label, 2-period crossover, food effect cohort.
What is the current status of trial NCT04154501?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2018-12-04. Estimated completion is 2019-08-26.
What conditions does trial NCT04154501 study?
This clinical trial studies the following conditions: Pain, Chronic Pain, Nociceptive Pain.
What interventions are being tested in trial NCT04154501?
The interventions under investigation include: Other: Placebo (OTHER), CNTX-6016 (DRUG).
Who is sponsoring clinical trial NCT04154501?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04154501 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04154501's enrollment target sits among peer trials
68 217th of 374 higher than 155 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RECRUITING · Phase 1
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Phase 1 Study of SBS-147 in Healthy Adults
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI